J&J Medical Connect
IMAAVY®

(nipocalimab-aahu)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY - Long-term Phase 3 Safety and Efficacy in Adult Patients with Generalized Myasthenia Gravis

Last Updated: 10/20/2026

SUMMARY

  • In an open-label extension (OLE) phase of a 24-week, phase 3, randomized, double-blind (DB), placebo (PBO)-controlled trial in adult patients with generalized myasthenia gravis (gMG)1,2:
    • The mean (standard error [SE]) from DB baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score was -6.47 (1.20) in the IMAAVY → IMAAVY + standard of care (SOC) group and -6.69 (0.85) in the PBO → IMAAVY + SOC group at OLE week 96.2
    • No cases of unexpected adverse events (AEs) were reported during the OLE phase.3

Clinical data

VIVACITY-MG3

Antozzi et al (2025)1,2 evaluated the efficacy and safety of IMAAVY in adults with gMG in a phase 3, randomized, multicenter, DB, PBO-controlled study.

Study Design/Methods

VIVACITY-MG3 Study Design1,2,4

Abbreviations: AchR+, acetylcholine receptor positive; COVID-19,coronavirus disease 2019; EU, European Union; IV, intravenous; LD, loading dose; MG-ADL, Myasthenia Gravis-Activities of Daily Living; MGFA,Myasthenia Gravis Foundation of America; MuSK+, muscle-specific tyrosine kinase ositive; OLE, open-label extension; Q2W, every 2 weeks; R, randomized; SOC, standard-of-care; US, United States; W, week.
aIn the EU, the OLE phase will be up to 240 weeks.
bRandomization was stratified by autoantibody status (anti-AChR+ and/or anti-MuSK+, anti-AChR negative and anti-MuSK negative), Day 1 MG-ADL total score (≤9, >9), and region (East Asia, US, rest of world).
cSOC includes acetylcholinesterase inhibitor, glucocorticosteroid, and/or immunosuppressant.
dDue to the COVID-19 pandemic, some patients from the phase 2 study (NCT03772587) were unable to enter the phase 2 OLE study (NCT03896295). These patients could directly enter the phase 3 OLE and their data will be disclosed later.
ePatients who withdraw or discontinue after receiving any amount of study intervention are required to complete a safety follow-up visit 8 weeks after their last dose.

Results


Baseline Demographics and Characteristics (Seropositive Population)2

IMAAVY → IMAAVY + SOC
PBO → IMAAVY + SOC
Analysis set: seropositive efficacya, n
71
66
Mean age, years (range)
51.1 (20-81)
51.6 (20-81)
Female, n (%)
46 (64.8)
38 (57.6)
Baseline MG-ADL total score, mean (SD)
9.3 (2.75)
9.0 (1.98)
Baseline QMG total score, mean (SD)
15.2 (4.85)b
15.6 (4.90)
Anti-AChR+/anti-MuSK+/anti-LRP4+, n
59/10/2
61/4/1
Abbreviations: AChR, acetylcholine receptor; DB, double-blind; LRP4, low-density lipoprotein receptor-related protein 4; MG-ADL, Myasthenia Gravis Activities of Daily Living; MuSK, muscle-specific tyrosine kinase; OLE, open-label extension; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SD, standard deviation; SOC, standard of care.
aAll randomized seropositive patients who received ≥1 dose of study intervention in the DB phase or all seropositive patients who received ≥1 dose of IMAAVY in the OLE phase.
bn=67

Efficacy
  • A total of 137 patients with antibody-positive gMG were treated with IMAAVY in the OLE phase with a follow-up duration of over 96 weeks.2
  • At OLE week 96, the mean (SE) change from DB baseline in the MG-ADL total score was -6.47 (1.20) in the IMAAVY → IMAAVY + SOC group, -6.69 (0.85) in the PBO → IMAAVY + SOC group and -6.58 (0.71) in the overall IMAAVY + SOC group. See Figure: Mean Change in the MG-ADL Total Score from DB Baseline (Seropositive Population).2

Mean Change in the MG-ADL Total Score from DB Baseline (Seropositive Population)2

Abbreviations: DB, double-blind; MG-ADL, Myasthenia Gravis Activities of Daily Living; Nipo, nipocalimab; OL, open-label; OLE, open-label extension; PBO, placebo; SE, standard error; W, week.

Mean Change in the QMG Total Score from DB Baseline (Seropositive Population)2

Abbreviations: DB, double-blind; OL, open-label; Nipo, nipocalimab; OLE, open-label extension; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SE, standard error; W, week.

Safety

Safety and Tolerability (Exposure Adjusted Incidence Rate)3
OLE All IMAAVY
Analysis set, n
176
Average follow-up duration, weeks
70.53
PYa
237.9
Events/PY
Events, n
Patients, nb
All AEs
5.59
1331
159
Serious AEs
0.31
74
46
Fatal AEs
0.02
4
4
Treatment discontinuation due to AEsc
0.05
13
13
Infections and infestations
1.39
330
125
Infusion-related reactionsd
0.07
17
10
Adjudicated MACE, fatal
0.01
3
3
Adjudicated MACE, not fatal
0.03
7
1
Abbreviations: AE, adverse event; DB, double-blind; eCRF, electronic case report form; MACE, major adverse cardiac events; OLE, open-label extension; PY, patient years.
aPY of observation is calculated as the total duration of follow-up in days/365.25.
bPatients with ≥1 AE are shown.
cPermanent discontinuation of treatment. Treatment discontinuation for an AE with onset in the DB (or OLE) phase occurred in the DB (or OLE) phase.
dIndicated as infusion reaction by investigator on eCRF and relationship to study intervention= “Related”.


AEs by Preferred Term (Exposure Adjusted Incidence Rate)3
OLE All IMAAVY (n=176)
PYa
237.9
Events/PYa
Events, n
Patients, nb
Upper respiratory tract infection
0.21
50
39
Nasopharyngitis
0.18
44
33
COVID-19
0.11
25
23
Urinary tract infection
0.12
28
19
Back pain
0.09
22
18
Muscle spasms
0.08
19
12
Pain in extremity
0.05
11
10
Arthralgia
0.08
18
13
Myasthenia gravis
0.20
48
31
Headache
0.21
50
29
Dizziness
0.02
5
4
Peripheral edema
0.04
10
9
Pyrexia
0.05
11
10
Diarrhea
0.08
20
20
Nausea
0.04
10
8
Cough
0.04
10
9
Rash
0.02
5
4
Anemia
0.03
7
7
Insomnia
0.02
4
4
Abbreviations: AE, adverse event; COVID-19, coronavirus disease 2019; OLE, open-label extension; PY, patient years.
aPY of observation is calculated as the total duration of follow-up in days/365.25.
bPatients with ≥1 AE are shown. AEs listed where system organ class event rate (number of events/PY) is ≥0.1 or preferred term event rate (number of events/PY) is ≥0 in either treatment group.

Pharmacodynamics

Total IgG Reduction from Baseline (Seropositive Population)2

Abbreviations: DB, double-blind; IgG, immunoglobulin G; Nipo, nipocalimab; OL, open-label; OLE, open-label extension; PBO, placebo; SE, standard error; W, week.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 24 September 2026.

References

1 Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116.  
2 Antozzi C, Vu T, Ramchandren S, et al. Long-term safety and efficacy of nipocalimab: approximately 2 years follow-up results from the open-label extension phase of Vivacity-MG3 study. Poster presented at: The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; September 29-October 2, 2026; Orlando, FL.  
3 Katzberg H, Ait-Tihyaty M, Turkoz I, et al. Safety profile of nipocalimab, a new neonatal fragment crystallizable receptor blocker in the phase 3 Vivacity study. Poster presented at: 15th Myasthenia Gravis Foundation of America (MGFA) International Conference; May 13-15, 2025; The Hague, The Netherlands.  
4 Antozzi C, Vu T, Ramchandren S, et al. Supplement to: Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116.  
5 Vu T, Antozzi C, Ramchandren S, et al. Efficacy and safety of nipocalimab in patients with generalized myasthenia gravis - top line results from the double-blind, placebo-controlled, randomized phase 3 Vivacity-MG3 study. Poster presented at: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; October 15-18, 2024; Savannah, GA.  

Would you like to clear and leave your conversation? Message history will be lost.